Corvus Pharmaceuticals
CRVS
53 hedge funds and large institutions have $250M invested in Corvus Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 16 reducing their positions, and 0 closing their positions.
83.62% more ownership
Funds ownership: 0% → 83.62% (+84%)
18% more funds holding
Funds holding: 45 → 53 (+8)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 16
7% less capital invested
Capital invested by funds: $267M → $250M (-$17.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$19.4M |
| 2 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$6.35M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$549K |
| 4 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$324K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$244K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$6.51M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$787K |
| 3 |
Millennium Management
New York
|
-$778K |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$391K |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$237K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Barclays
London,
United Kingdom
| $2K | +$2.11K | +139 | +662% |
|
52
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | +$2.4K | +158 | New |
|
53
BNP Paribas Financial Markets
Paris,
France
| $615 | -$2.77K | -182 | -81% |
|
CRVS Hedge Fund Activity: Q4 2016 in Review
53 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q4 2016, worth a combined $250M — down 6.5% from $267M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new CRVS positions and 0 closed out — a net gain of 9 holders — while 15 added to existing stakes and 16 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $19.4M. The largest seller was BlackRock Advisors, cutting an estimated $6.51M.
- 53 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q4 2016, up from 45 in Q3 2016.
- Funds reported $250M of Corvus Pharmaceuticals stock for Q4 2016, down 6.5% quarter-over-quarter.
- 9 funds opened new Corvus Pharmaceuticals positions in Q4 2016 and 0 closed out, a net change of +9 holders.
- The largest Corvus Pharmaceuticals buyer in Q4 2016 was Fidelity Investments, an estimated $19.4M added.
- The largest Corvus Pharmaceuticals seller in Q4 2016 was BlackRock Advisors, an estimated $6.51M sold.
Based on aggregated 13F filings for Q4 2016.